glp-1 peptide sequence Multifaceted Roles of and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective Amino acid sequence alignment of

Funding A

(2025) T2DM: 46.5% discontinued by 1 year 64.1% discontinued by 2 years Without T2DM: 64.8% discontinued by 1 year 84.4% discontinued by 2 years Key Factors Linked to Discontinuation: Higher rates among patients without T2DM Age 65 years More likely to discontinue Higher weight loss during treatment Associated with lower discontinuation rates Moderate to severe GI side effects Higher likelihood of stopping treatment Higher income (T2DM only) Lower discontinuation rates Reinitiation of GLP-1: Source: Rodriguez PJ, Zhang V, Gratzl S, et al

Granted, there are some hidden costs involved

Interestingly, chemolithotrophs also capture reducing power, albeit obtained from oxidation of inorganic compounds rather than from photons of light, as NADPH